Srini Ramanathan, Ph.D. is Chief Executive Officer of 858 Therapeutics. He is a drug developer and company builder with more than two decades of experience across public and venture-backed companies, and has contributed to the approval of 12 medicines across oncology, immunology and virology.

Most recently, Dr. Ramanathan served as Chief Development Officer of Aditum Bio, leading development of its portfolio programs. Before that, he was Chief Development Officer at Roivant Sciences, where he drove company creation and development across multiple portfolio companies, including Telavant and Pulmovant. He led R&D strategy and development for Telavant from in-licensing through Phase 3 readiness and its $7.25 billion acquisition by Roche.

Earlier, as Senior Vice President of R&D Sciences at Horizon Therapeutics, he helped build the company’s research and development organization and pipeline, and contributed to the approval of Tepezza®, the first treatment for thyroid eye disease. He previously held development leadership roles at AbbVie and spent 13 years at Gilead Sciences, where he led clinical pharmacology and contributed to 10 global approvals in HIV, HCV and oncology.

Dr. Ramanathan holds a Ph.D. in Pharmaceutics from Rutgers University, an M.S. in Pharmaceutics from Duquesne University and a B.Pharm (Hons) from the Birla Institute of Technology and Science (BITS), Pilani, India.